Exagen to Announce Fourth Quarter and Full Year Financial Results on March 20, 2023
Exagen Inc. (Nasdaq: XGN) will announce its financial results for the fourth quarter and full year ended December 31, 2022, on March 20, 2023, after market close.
Sentiment and the balance of points
Rhea-AI Sentiment reads the wording of the document, how positive or negative its language is on a 1 to 5 scale. The balance of points shown with the takes weighs what the document actually discloses, so the two can disagree, for example when a trial that missed its main goal is described in upbeat language.
Rhea-AI Summary
Exagen Inc. (Nasdaq: XGN) will announce its financial results for the fourth quarter and full year ended December 31, 2022, on March 20, 2023, after market close. CEO John Aballi and CFO Kamal Adawi will discuss these results in a conference call at 4:30 PM ET. Interested listeners can dial (201) 389-0918 for U.S. participants or (877) 407-0890 for international attendees. A replay will be available until April 3, 2023. Exagen specializes in autoimmune diagnostic testing solutions, focusing on precision medicine to assist patients and healthcare providers.
Positive
- Plans to release financial results after market close, allowing investors to gauge performance.
- Focus on precision medicine could enhance market position and growth.
Negative
- None.
Details
News Market Reaction – XGN
The recorded move for XGN in the trading session of this news was -2.26%.
Data tracked by StockTitan Argus. Session date unavailable.
AI-generated analysis. How Rhea-AI works. Not financial advice.
SAN DIEGO, March 06, 2023 (GLOBE NEWSWIRE) -- Exagen Inc. (Nasdaq: XGN), a leading provider of autoimmune testing solutions, will release financial results for the quarter and year ended December 31, 2022, after the market close on Monday, March 20, 2023. John Aballi, Exagen’s President and Chief Executive Officer, and Kamal Adawi, Chief Financial Officer, will host a conference call to review the Company’s results at 4:30 PM ET (1:30 PM PT).
Interested parties may access the conference call by dialing (201) 389-0918 (U.S.) or (877) 407-0890 (international). Participants wishing to access the call via webcast should use the link posted on the Exagen investor relations website at investors.exagen.com.
A replay of the conference call will be available until Monday, April 3, 2023, at 11:59 PM ET (8:59 PM PT). Interested parties may access the replay of the conference call by dialing (201) 612-7415 (U.S.) or (877) 660-6853 (international) using passcode 13736103. Additionally, a recording of the webcast will be available using the link on the Exagen investor relations website approximately one hour after the call concludes.
About Exagen Inc.
Exagen is a leading provider of autoimmune diagnostic, prognostic, and monitoring testing solutions. Exagen is a patient focused, discovery driven organization built on the success of AVISE® testing and is investing in its product pipeline to support patients throughout their autoimmune diagnosis and treatment journeys. The goal at Exagen is to assist patients, physicians, and payors by enabling precision medicine. Exagen is located in San Diego County.
For more information, please visit Exagen.com and follow @ExagenInc on Twitter.
CONTACTS:
Investor Relations
Exagen Inc.
Ryan Douglas
rdouglas@exagen.com
760.560.1525
Company
Exagen Inc.
Kamal Adawi, Chief Financial Officer
kadawi@exagen.com
FAQ
AI-generated questions and answers. How Rhea-AI works. Not financial advice.